Andrew Young

Andrew Young

Company: i2o Therapeutics

Job title: Chief Medical Officer


Revealing Current Modes of Delivery for Enhanced Tolerability & Envisioning Future Strategies for Further Improvement 9:30 am

Assessing the different modes of delivery for GLP-1 treatments Considering the need to improve tolerability methods for GLP-1 treatments to assess the balance between the impact of side effects versus the impact of weight loss Assessing the benefits and drawbacks of different modes of delivery to improve tolerability of GLP-1s to discern their effectiveness at…Read more

day: Conference Day Two

Panel Discussion: Discussing the Future Indications of GLP-1-Based Therapeutics – Promises & Challenges 2:30 pm

Advancing the reach of GLP-1-based treatments into other therapeutic areas, particularly Alzheimer’s and Parkinson’s disease Exploring the scientific validity of the latest treatment frontiers with GLP-1s to understand the potential in these areas Considering the commercial possibilities of these new therapeutic area markets to grasp the scope of opportunityRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.